Interplay between vitamin D and the drug metabolizing enzyme CYP3A4

Journal of Steroid Biochemistry and Molecular Biology

Volumn 136, Issue 1, 2013, Pages 54-58

  Wang, Zhican ^a   Schuetz, Erin G ^b   Xu, Yang ^a,c   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c AMGEN INC   (United States)

Author keywords

Cytochrome P450 3A4; Drug metabolism; Enterohepatic circulation; Osteomalacia; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA GLUCURONIDASE; CALCITONIN; CALCITRIOL; CARBAMAZEPINE; CYTOCHROME P450 3A4; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; VALPROIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

BASOLATERAL MEMBRANE; BILIARY EXCRETION; BIOTRANSFORMATION; CALCIUM ABSORPTION; CHRONIC LIVER DISEASE; COLON; CONJUGATION; CORRELATION ANALYSIS; DNA RESPONSIVE ELEMENT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; ENZYME INDUCTION; ENZYME SUBSTRATE; FIBROBLAST; GLUCURONIDATION; HUMAN; HYDROLYSIS; HYDROXYLATION; INHIBITION KINETICS; INTESTINE CELL; INTESTINE MUCOSA; KIDNEY TUBULE EPITHELIUM; LIVER CIRRHOSIS; LYMPHOCYTE; MACROPHAGE; NONHUMAN; OSTEOMALACIA; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; XENOBIOTIC METABOLISM;

EID: 84881155561     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.09.012     Document Type: Review

References (71)

1. LA Plum, H.F. DeLuca, Vitamin D, disease and therapeutic opportunities, Nature Reviews Drug Discovery 9 (12) (2010) 941-955.
2. M.R. Haussler, G.K. Whitfield, CA Haussler, J.C. Hsieh, P.D. Thompson, S.H. Selznick, C.E. Dominguez, P.W. Jurutka, The nuclear vitamin D receptor: biological and molecular regulatory properties revealed, Journal of Bone and Mineral Research 13 (3) (1998) 325-349. (Pubitemid 28146215)
3. M.R. Haussler, P.W. Jurutka, M. Mizwicki, A.W. Norman, Vitamin D receptor (VDR)-mediated actions of 1alpha, 25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms, Best Practice and Research. Clinical Endocrinology and Metabolism 25 (4) (2011) 543-559.
4. F.P. Guengerich, Cytochrome P-450 3A4: regulation and role in drug metabolism, Annual Review of Pharmacology and Toxicology 39 (1999) 1-17. (Pubitemid 29222549)
5. P.B. Watkins, SA Wrighton, E.G. Schuetz, D.T. Molowa, P.S. Guzelian, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, Journal of Clinical Investigation 80 (4) (1987) 1029-1036. (Pubitemid 18075638)
6. J.H. Lin, CYP induction-mediated drug interactions: in vitro assessment and clinical implications, Pharmaceutical Research 23 (6) (2006) 1089-1116. (Pubitemid 43946134)
7. P. Schmiedlin-Ren, K.E. Thummel, J.M. Fisher, M.F. Paine, K.S. Lown, P.B. Watkins, Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3, Molecular Pharmacology 51 (5) (1997) 741-754. (Pubitemid 27224679)
8. H. Hara, Y. Yasunami, T. Adachi, Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells, Biochemical and Biophysical Research Communications 296 (1) (2002) 182-188. (Pubitemid 35002076)
9. J. Fan, S. Liu, Y. Du, J. Morrison, R. Shipman, K.S. Pang, Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha, 25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer, Journal of Pharmacology and Experimental Therapeutics 330 (2) (2009) 389-402.
10. S. Fukumori, T. Murata, M. Taguchi, Y. Hashimoto, Rapid and drastic induction ofCYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells, Drug Metabolism and Pharmacokinetics 22 (5) (2007) 377-381.
11. X.E. Zheng, Z. Wang, M.Z. Liao, Y.S. Lin, M.C. Shuhart, E.G. Schuetz, K.E. Thummel, Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha, 25-dihydroxyvitamin D(3) function in human colon adenocarcinoma LS180 cells, Biochemical Pharmacology 84 (3) (2012)391-401.
12. G. Elizondo, I.M. Medina-Diaz, Induction of CYP3A4 by 1alpha, 25-dyhydroxyvitamin D3 in HepG2 cells, Life Sciences 73 (2) (2003) 141-149. (Pubitemid 36555934)
13. L. Drocourt, J.C. Ourlin, J.M. Pascussi, P. Maurel, M.J. Vilarem, Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes, Journal of Biological Chemistry 277 (28) (2002) 25125-25132. (Pubitemid 34951818)
14. Y. Xu, K. Iwanaga, C. Zhou, M.J. Cheesman, F. Farin, K.E. Thummel, Selective induction of intestinal CYP3A23 by 1alpha, 25-dihydroxyvitamin D3 in rats, Biochemical Pharmacology 72 (3) (2006) 385-392. (Pubitemid 43975082)
15. AA Khan, B.S. Dragt, R.J. Porte, G.M. Groothuis, Regulation of VDR expression in rat and human intestine and liver-consequences for CYP3A expression, Toxicology In Vitro 24 (3) (2012) 822-829.
16. K.E. Thummel, C. Brimer, K. Yasuda, J. Thottassery, T. Senn, Y. Lin, H. Ishizuka, E. Kharasch, J. Schuetz, E. Schuetz, Transcriptional control of intestinal cytochrome P-4503A by 1alpha, 25-dihydroxy vitamin D3, Molecular Pharmacology 60 (6)(2001) 1399-1406.
17. P.D. Thompson, P.W. Jurutka, G.K. Whitfield, S.M. Myskowski, K.R. Eichhorst, C.E. Dominguez, CA. Haussler, M.R. Haussler, Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements, Biochemical and Biophysical Research Communications 299 (5) (2002)730-738. (Pubitemid 36034548)
18. P. Pavek, K. Pospechova, L. Svecova, Z. Syrova, L. Stejskalova, J. Blazkova, Z. Dvorak, J. Blahos, Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene, Biochemical Pharmacology 79 (2) (2010)277-287.
19. P.W. Jurutka, P.D. Thompson, G.K. Whitfield, K.R. Eichhorst, N. Hall, C.E. Dominguez, J.C. Hsieh, CA Haussler, M.R. Haussler, Molecular and functional comparison of 1, 25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4, Journal of Cellular Biochemistry 94 (5) (2005) 917-943. (Pubitemid 41420254)
20. M. Makishima, T.T. Lu, W. Xie, G.K. Whitfield, H. Domoto, R.M. Evans, M.R. Haussler, D.J. Mangelsdorf, Vitamin D receptor as an intestinal bile acid sensor, Science 296 (5571) (2002) 1313-1316. (Pubitemid 34522785)
21. Y. Yasunami, H. Hara, T. Iwamura, T. Kataoka, T. Adachi, C-jun N-terminal kinase modulates 1, 25-dihydroxyvitamin D3-induced cytochrome P450 3A4 gene expression, Drug Metabolism and Disposition: The Biological Fate of Chemicals 32 (7) (2004) 685-688. (Pubitemid 38821868)
22. J.M. Pascussi, S. Gerbal-Chaloin, L. Drocourt, P. Maurel, M.J. Vilarem, The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors, Biochimica et Biophysica Acta 1619 (3) (2003) 243-253. (Pubitemid 36163419)
23. P. Pavek, Z. Dvorak, Xenobiotic-induced transcriptional regulation of xeno-biotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues, Current Drug Metabolism 9 (2) (2008) 129-143. (Pubitemid 351461002)
24. M. Gascon-Barre, C. Demers, A. Mirshahi, S. Neron, S. Zalzal, A. Nanci, The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells, Hepatology 37 (5) (2003) 1034-1042. (Pubitemid 36538680)
25. R.K. Thirumaran, J.K. Lamba, R.B. Kim, B.L Urquhart, J.C. Gregor, N. Chande, Y. Fan, A. Qi, C. Cheng, K.E. Thummel, S.D. Hall, E.G. Schuetz, Intestinal, CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation, Biochemical Pharmacology 84 (1) (2012) 104-112.
26. J.B. Schwartz, Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence, Clinical Pharmacology and Therapeutics 85 (2) (2009) 198-203.
27. J.D. Lindh, M.L. Andersson, E. Eliasson, L. Bjorkhem-Bergman, Seasonal variation in blood drug concentrations and a potential relationship to vitamin D, Drug Metabolism and Disposition: The Biological Fate of Chemicals 39 (5) (2011) 933-937.
28. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, K.E. Thummel, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism, Journal of Pharmacology and Experimental Therapeutics 283 (3)(1997) 1552-1562. (Pubitemid 28016533)
29. M. Gascon-Barre, M. Gamache, Contribution of the biliary pathway to the homeostasis of vitamin D3 and of 1, 25-dihydroxyvitamin D3, Endocrinology 129 (5)(1991) 2335-2344.
30. R.W. Gray, A.E. Caldas, D.R. Wilz, J. Lemann Jr., G.A. Smith, H.F. DeLuca, Metabolism and excretion of 3H-1, 25-(OH)2-vitamin D3 in healthy adults, Journal of Clinical Endocrinology and Metabolism 46 (5) (1978) 756-765. (Pubitemid 8345867)
31. J.E. Ledger, G.J. Watson, C.C. Ainley, J.E. Compston, Biliary excretion of radioactivity after intravenous administration of 3H-1, 25-dihydroxyvitamin D3 in man, Gut 26 (11) (1985) 1240-1245. (Pubitemid 16216272)
32. R. Kumar, S. Nagubandi, V.R. Mattox, J.M. Londowski, Enterohepatic physiology of 1, 25-dihydroxyvitamin D3, Journal of Clinical Investigation 65 (2) (1980) 277-284.
33. R.H. Wiesner, R. Kumar, E. Seeman, V.L. Go, Enterohepatic physiology of 1, 25-dihydroxyvitamin D3 metabolites in normal man, Journal of Laboratory and Clinical Medicine 96 (6) (1980) 1094-1100. (Pubitemid 11200104)
34. S.B. Arnaud, R.S. Goldsmith, P.W. Lambert, V.L Go, 25-HydroxyvitaminD3: evidence of an enterohepatic circulation in man, Proceedings of the Society for Experimental Biology and Medicine 149 (2) (1975) 570-572.
35. M. Gascon-Barre, Biliary excretion of [3H]-25-hydroxyvitamin D3 in the vitamin D-depleted rat, American Journal of Physiology 242 (5) (1982) G522-G532. (Pubitemid 12100001)
36. M. Gascon-Barre, Is there any physiological significance to the enterohepatic circulation of vitamin D sterols? Journal of the American College of Nutrition 5 (3) (1986)317-324.
37. K. Shimada, K. Mitamura, I. Nakatani, Characterization of monoglucuronides of vitamin D2 and 25-hydroxyvitamin D2 in rat bile using high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry, Journal of Chromatography B, Biomedical Sciences and Applications 690(1-2)(1997)348-354. (Pubitemid 27136490)
38. A. Shimoyamada, S. Tomiyama, M. Shimizu, K. Yamamoto, S. Kunii, S. Yamada, In vivo metabolism of 24R, 25-dihydroxyvitamin D3: structure of its majorbile metabolite, Biochimica et Biophysica Acta 1346 (2) (1997) 147-157. (Pubitemid 27268391)
39. T. Higashi, M. Horike, R. Kikuchi, K. Shimada, In vitro and in vivo glucuronidation of 24, 25-dihydroxyvitamin D3, Steroids 64 (10) (1999) 715-725.
40. T. Higashi, K. Miura, R. Kikuchi, K. Shimada, H. Hiyamizu, H. Ooi, Y. Iwabuchi, S. Hatakeyama, N. Kubodera, Characterization of new conjugated metabolites in bile of rats administered 24, 25-dihydroxyvitamin D(3) and 25-hydroxyvitamin D(3), Steroids 65 (5) (2000) 281-294. (Pubitemid 30177348)
41. T. Hashizume, Y. Xu, M.A. Mohutsky, J. Alberts, C. Hadden, T.F. Kalhorn, N. Isoherranen, M.C. Shuhart, K.E. Thummel, Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha, 25-dihydroxyvitamin D3 conjugation, Biochemical Pharmacology 75 (5) (2008) 1240-1250.
42. J.P. Goff, N.J. Koszewski, J.S. Haynes, R.L. Horst, Targeted delivery of vitamin D to the colon using beta-glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease, American Journal of Physiology. Gastrointestinal and Liver Physiology 302 (4) (2012) G460-G469.
43. D.D. Bikle, Vitamin D: an ancient hormone, Experimental Dermatology 20 (1) (2011)7-13.
44. F. Perwad, A.A. Portale, Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblastgrowth factor23, MolecularandCellularEndocrinol-ogy 347 (1-2) (2011) 17-24.
45. D. Bikle, Nonclassic actions of vitamin D, Journal of Clinical Endocrinology and Metabolism 94 (1) (2009) 26-34.
46. J.S. Adams, M. Hewison, Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase, Archives of Biochemistry and Biophysics 523 (1) (2012) 95-102.
47. G. Jones, D.E. Prosser, M. Kaufmann, 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D, Archives of Biochemistry and Biophysics 523 (1) (2012) 9-18.
48. T. Sakaki, N. Sawada, K. Komai, S. Shiozawa, S. Yamada, K. Yamamoto, Y. Ohyama, K. Inouye, Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24, European Journal of Biochemistry 267 (20) (2000) 6158-6165.
49. D.E. Prosser, G. Jones, Enzymes involved in the activation and inactivation of vitamin D, Trends in Biochemical Sciences 29 (12) (2004) 664-673. (Pubitemid 39491265)
50. H.J. Armbrecht, K. Okuda, N. Wongsurawat, R.K. Nemani, M.L. Chen, M.A. Boltz, Characterization and regulation of the vitamin D hydroxylases, Journal of Steroid Biochemistry and Molecular Biology 43 (8) (1992) 1073-1081. (Pubitemid 23044722)
51. R.P. Gupta, B.W. Hollis, S.B. Patel, K.S. Patrick, N.H. Bell, CYP3A4 is a human microsomal vitamin D 25-hydroxylase, Journal of Bone and Mineral Research 19 (4)(2004)680-688. (Pubitemid 41071229)
52. R.P. Gupta, Y.A. He, K.S. Patrick, J.R. Halpert, N.H. Bell, CYP3A4 is a vitamin D-24-and 25-hydroxylase: analysis of structure function by site-directed mutagenesis, Journal of Clinical Endocrinology and Metabolism 90 (2) (2005) 1210-1219. (Pubitemid 40279256)
53. Y. Xu, T. Hashizume, M.C. Shuhart, C.L. Davis, W.L. Nelson, T. Sakaki, T.F. Kalhorn, P.B. Watkins, E.G. Schuetz, K.E. Thummel, Intestinal and hepatic CYP3A4 catalyze hydroxylationof 1alpha, 25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia, Molecular Pharmacology 69 (1) (2006) 56-65. (Pubitemid 43048893)
54. Z. Wang, Y.S. Lin, X.E. Zheng, T. Senn, T. Hashizume, M. Scian, L.J. Dickmann, S.D. Nelson, T.A. Baillie, M.F. Hebert, D. Blough, C.L. Davis, K.E. Thummel, An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway, Molecular Pharmacology 81 (4) (2012) 498-509.
55. Z. Wang, T. Senn, T. Kalhorn, X.E. Zheng, S. Zheng, C.L. Davis, M.F. Hebert, Y.S. Lin, K.E. Thummel, Simultaneous measurement of plasma vitamin D(3) metabolites, including 4beta, 25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry, Analytical Biochemistry 418 (1) (2011)126-133.
56. A.M. Pack, B. Gidal, B. Vazquez, Bone disease associated with antiepileptic drugs, Cleveland Clinic Journal of Medicine 71 (Suppl. 2) (2004) S42-S48. (Pubitemid 41830287)
57. A.M. Pack, M.J. Morrell, Epilepsy and bone health in adults, Epilepsy & Behavior 5 (Suppl. 2) (2004) S24-S29. (Pubitemid 38404510)
58. A.M. Pack, Treatment of epilepsy to optimize bone health, Current Treatment Options in Neurology 13 (4) (2011)346-354.
59. S.C. Shah, R.K. Sharma, Hemangini, A.R. Chitle, Rifampicin induced osteomalacia, Tubercle 62 (3) (1981) 207-209. (Pubitemid 11062334)
60. M.J. Brodie, A.R. Boobis, C.J. Hillyard, G. Abeyasekera, J.C. Stevenson, I. Mac-Intyre, B.K. Park, Effect of rifampicin and isoniazid on vitamin D metabolism, Clinical Pharmacology and Therapeutics 32 (4) (1982) 525-530. (Pubitemid 13096730)
61. P. Peterson, P. Gray, K.G. Tolman, Calcium balance in drug-induced osteomalacia: response to vitamin D, Clinical Pharmacology and Therapeutics 19 (1) (1976) 63-67.
62. A. Bhan, A.D. Rao, D.S. Rao, Osteomalacia as a result of vitamin D deficiency, Endocrinology and Metabolism Clinics of North America39 (2) (2010)321-331.
63. M.J. Brodie, A.R. Boobis, C.T. Dollery, C.J. Hillyard, D.J. Brown, I. MacIntyre, B.K. Park, Rifampicin, vitamin, Rifampicin and vitamin D metabolism, Clinical Pharmacology and Therapeutics 27 (6) (1980) 810-814.
64. R.H. Lee, K.W. Lyles, C. Colon-Emeric, A review of the effect of anticonvulsant medications on bone mineral density and fracture risk, The American Journal of Geriatric Pharmacotherapy 8 (1) (2010)34-46.
65. T.J. Hahn, S.J. Birge, C.R. Scharp, L.V. Avioli, Phenobarbital-induced alterations in vitamin D metabolism, Journal of Clinical Investigation 51 (4) (1972) 741-748.
66. M. Gascon-Barre, S. Vallieres, P.M. Huet, Influence of phenobarbital on the hepatic handling of [3H]vitamin D3 in the dog, American Journal of Physiology 251 (5 Pt. 1) (1986) G627-G635.
67. J.M. Pascussi, A. Robert, M. Nguyen, O. Walrant-Debray, M. Garabedian, P. Martin, T. Pineau, J. Saric, F. Navarro, P. Maurel, M.J. Vilarem, Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia, Journal of Clinical Investigation 115 (1) (2005) 177-186. (Pubitemid 40385519)
68. C. Zhou, M. Assem, J.C. Tay, P.B. Watkins, B. Blumberg, E.G. Schuetz, K.E. Thummel, Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia, Journal of Clinical Investigation 116 (6)(2006)1703-1712.
69. M. von Borstel Smith, K. Crofoot, R. Rodriguez-Proteau, T.M. Filtz, Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells, Toxicology In Vitro 21 (5) (2007) 855-862. (Pubitemid 46603245)
70. L.Y. Lim, N. Chalasani, Vitamin D deficiency in patients with chronic liver disease and cirrhosis, Current Gastroenterology Reports 14 (1) (2012) 67-73.
71. D.J. McConn 2nd, Y.S. Lin, T.L. Mathisen, D.K. Blough, Y. Xu, T. Hashizume, S.L. Taylor, K.E. Thummel, M.C. Shuhart, Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis, Clinical Pharmacology and Therapeutics 85 (4) (2009) 387-393.